Servier Pharmaceuticals
Buying intent
32 tracked signals | Top 15 topics are below | Marketing and Operations are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Servier Pharmaceuticals's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
15d ago
15d ago
4d ago
7d ago
13d ago
10d ago
2d ago
4d ago
30d ago
4d ago
15d ago
15d ago
13d ago
8d ago
6d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Servier Pharmaceuticals
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
See everyone, not just the first 10
16 people across every department at Servier Pharmaceuticals, plus a LinkedIn profile link for each.
Primary products / business lines
LinkedIn company profileServier Pharmaceuticals is a Boston-based, commercial-stage biopharmaceutical company. As the U.S. subsidiary of Servier Group, Servier is governed by a non-profit foundation, enabling the company to approach innovation with a long-term vision centered on the patient, free of influence from outside investors and short-term market pressures. Launched in the U.S. in 2018, Servier Pharmaceuticals i
Top accounts researching Servier Pharmaceuticals
names withheld on the public pageThese are companies whose own people brought up Servier Pharmaceuticals unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
66,174 companies · 318,882 people are researching Hiring
Servier Pharmaceuticals's own team shows 3 signals on this topic. No one outside Servier Pharmaceuticals has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Leadership Development21,190 cos · 76,064 people
- Agentic AI System30,546 cos · 119,561 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Marketing — 3 people; Sales — 3 people; Leadership — 1 person; Operations — 1 person
What's been said
public posts by Servier Pharmaceuticals's teamNo public post naming Servier Pharmaceuticals has surfaced in the past year, so this is what Servier Pharmaceuticals's own team is posting about publicly — their topics, in their words.
An estimated 108,810 people will receive a new primary brain tumor diagnosis in 2026, according to the National Brain Tumor Society. Thousands of them will be children. Servier’s research now extends into pediatric low-grade glioma, complementing our leadership in adult IDH-mutant glioma. Two diseases, two different patient populations, one shared gap: not enough targeted options. We are focused on closing that gap in patients of all ages. This #BrainTumorAwarenessMonth , we recognize the patients and families who have been impacted by this disease and reaffirm our commitment to you – today and every day. #GoGrayinMay #BTAM #braintumor #cancer #oncology
May 2026